NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

f3tt3f.


Is this the exchange and trial you were referring to?

We reported positive interim data from our ongoing CAN-003 clinical trial of CVac in ovarian cancer in both October and November of 2012. This interim data was presented at the International Gynaecological Cancer Society meeting by Dr. Jeffery Goh and co-investigators. And in this interim analysis, there were encouraging trends of increased progression free survival for patients receiving CVac compared to the control group in the ongoing CAN-003 trial. Based on these initial analyses of seven patients from CAN-003, we were also able to demonstrate that CVac induces a mucin-1 specific T cell response in patients.

During the calendar year of 2013, we expect two important data points from the CAN-003 trial. In the third quarter of calendar year 2012, we plan to release the immune monitoring profile from all 63 patients in the trial over multiple time points during the course of the study. In the fourth quarter of calendar year 2013, we will have the final protocol analysis of progression free survival and the first evaluations of overall survival.

--- http://seekingalpha.com/article/1307231-prima-biomeds-ceo-discusses-f2q13-results-earnings-call-transcript?find=encouraging&all=false